Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
Author:
Letestu RémiORCID, Dahmani Abdelmalek, Boubaya Marouane, Baseggio Lucile, Campos Lydia, Chatelain Bernard, Debliquis Agathe, Drénou BernardORCID, Jacob Marie-Christine, Legac EricORCID, Le Garff-Tavernier Magali, Lhoumeau Anne-Catherine, Quiney Claire, Robillard Nelly, Ticchioni Michel, Aanei Carmen, Katsahian Sandrine, Delepine Roselyne, Vaudaux Sandrine, Rouillé Valérie, Béné Marie-Christine, Dartigeas Caroline, Van Den Neste Eric, Leprêtre Stéphane, Feugier Pierre, Cartron Guillaume, Leblond Véronique, Lévy Vincent, Cymbalista Florence, Cailleres Sylvie, Damaj Gandhi, Royer Bruno, Gardembas Martine, Dib Mamoun, Truchan-Graczyk Matgorzata, Hunault Mathilde, Foussard Charles, Corront Bernadette, Parry Anne, Orsini-Piocelle Frédérique, Trouillier Sébastien, Slama Bohiane, Lepeu Gérard, Zerazhi Hacene, Boulat Olivier, Azzedine Ahmed, Araujo Carla, Banos Anne, Bauduer Frédéric, Dutel Jean-Luc, Ghomari Kamel, Deconinck Eric, Brion Annie, Vuillier Jacqueline, Saad Alain, EL Yamani Abderrazak, Rodon Philippe, Soubeyran Pierre, Etienne Gabriel, Dilhuydy Marie-Sarah, Bouabdallah Krimo, Leguay Thibaut, Chouffi Bachra, Pollet Bertrand, Maakaroun Abdallah, Guillerm Gaëlle, Berthou Christian, Cheron Nathalie, André Marc, Vilque Jean Pierre, Fruchart Christophe, Voillat Laurent, Pica Gian Matteo, Corm Sélim, Micléa Jean-Michel, Souleau Bertrand, Molucon-Chabrot Cécile, De Renzis Benoit, Tournilhac Olivier, Bay Jacques-Olivier, Chaleteix Carine, Guieze Romain, Fleury Joel, Precupanu Cristina, Bouledroua Selwa, Haiat Stéphanie, Petitdidier Charlotte, Dupuis Jehan, Belhadj Karim, Casasnovas Olivier, Bastie Jean-Noel, Ferrant Emmanuelle, Gholam Dany, Molina Lysiane, Garban Frédéric, Tiab Mourad, Maisonneuve Hervé, Villemagne Bruno, Jacomy Dominique, Besson Caroline, Tertian Gérard, Laribi Kamel, Morel Pierre, Cazin Bruno, Moreau Stéphane, Reminieras Liliane, Rapp Marie-José, Moreau Philippe, Sebban Catherine, Michallet Anne-Sophie, Salles Gilles, Broussais Florence, Aurran-Schleinitz Thérèse, Coso Diane, Abarah Wajed, Kulekci Claire, Dorvaux Véronique, Carassou Philippe, Guibaud Isabelle, Christian Bernard, Graux Carlos, Rossi Jean-François, Quittet Philippe, Cartron Guillaume, Dubois Alain, Eisenmann Jean-Claude, Drénou Bernard, Morineau Nadine, Mahé Béatrice, Karsenti Jean-Michel, Jourdan Eric, Legouffe Eric, Alexis-Vigier Magda, Boulet Jean-Michel, Aoudjhane Malek, Thiéblemont Catherine, Andreoli Anna Lisa, Cymbalista Florence, Lévy Vincent, Dreyfus François, Leblond Véronique, Choquet Sylvain, Maloum Karim, Merle-Béral Hélène, Vekhoff Anne, Decaudin Didier, Brault Philippe, Delarue Richard, Janvier Maud, Soussain Carole, Vallantin Xavier, Sanhes Laurence, Dreyfus Brigitte, Tomowiak Cécile, Benramdane Riad, Gonzalez Hugo, Blaise-Brenna Anne, Kolb Brigitte, Delmer Alain, Dauriac Charles, Houot Roch, Escoffre-Barbe Martine, Lamy Thierry, De Guibert Sophie, Bernard Marc, Grosbois Bernard, Brehar Oana, Leprêtre Stéphane, Morice Patrick, Guyotat Denis, Jaubert Jérome, Portois Christelle, Fornecker Luc-Matthieu, Herbrecht Raoul, Bilger Karin, Ame Shanti, Ysebaert Loic, Dartigeas Caroline, Feugier Pierre, Godmer Pascal, Jardel Henry,
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference43 articles.
1. Thompson M, Brander D, Nabhan C, Mato A. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents. A review. JAMA Oncol. 2018;4:394–400. 2. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood.2016;127:279–86. 3. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929–36. 4. European Medicines Agency. Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies. EMA/629967/2014. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/12/WC500179047.pdf. Accessed 16 Sept 2019. 5. Appleby N, O’Brien D, Quinn FM, Smyth L, Kelly J, Parker I. et al. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leuk Lymphoma. 2018;59:1338–47.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|